MIRA PHARMACEUTICALS, INC. current report, 19 October 2023

Full document

Mira Pharmaceuticals, Inc. — Form 8-K Summary

Reporting period and context: Form 8-K reporting events dated October 19, 2023, with the filing signed October 25, 2023. The filing concerns changes to the company’s board and board committees, not financial results. Mira Pharmaceuticals is an emerging growth company whose common stock trades on Nasdaq under the symbol MIRA.

Key Financial Metrics

  • The filing does not provide revenue, profit, cash flow, margin, debt, liquidity, or other financial performance data.
  • The filing does not provide updated financial guidance or operating forecasts.

Material Changes

  • Brian Daly was unanimously elected and appointed to the Board of Directors on October 25, 2023.
  • Mr. Daly was appointed Chairperson of the Audit Committee and a member of the Compensation Committee.
  • David Vorhoff resigned from the Board on October 19, 2023. He had served as Chairperson of the Audit Committee and as a member of the Compensation Committee.
  • The company stated that Mr. Vorhoff’s resignation did not involve disagreements with the company, management, or the Board regarding operations, policies, or practices.

Management Commentary, Risks, and Unusual Items

  • Mr. Daly’s background includes more than 30 years on Wall Street and experience in investment banking, private equity, asset management, and startup advisory activities.
  • The filing contains no new business outlook, contingencies, litigation disclosures, financing information, or other unusual financial items.
  • The reported event date and filing chronology should be verified because the Form 8-K identifies October 19, 2023 as the earliest reported event, while the director appointment occurred on October 25, 2023.

Investor Verification Checklist

  • Verify the effective dates of Mr. Daly’s appointment and Mr. Vorhoff’s resignation.
  • Confirm the resulting composition and independence of the Audit and Compensation Committees.
  • Review subsequent filings for any related-party transactions, compensation arrangements, or additional board changes involving Mr. Daly.
  • Consult the company’s latest periodic report for financial condition, liquidity, cash runway, and operating outlook, none of which are addressed in this filing.